Evaluation of colposcopy after the addition of human papillomavirus testing to the Turkish cervical cancer screening program

Author:

Gunes Ali Can1ORCID,Ozgul Nejat2,Turkyılmaz Murat3,Kara Fatih3,Unlu Fahriye3,Ayhan Ali4,Gultekin Murat2ORCID

Affiliation:

1. Mamak State Hospital Department of Obstetrics and Gynecology Ankara Turkey

2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Hacettepe University Faculty of Medicine Ankara Turkey

3. Department of Cancer Control Turkish Ministry of Health, Public Health Institute Ankara Turkey

4. Department of Obstetrics and Gynecology Baskent University Faculty of Medicine Ankara Turkey

Abstract

AbstractObjectiveTo evaluate colposcopy performance following the human papillomavirus (HPV) DNA screening program in Turkey.MethodsWomen aged 30–65 years are screened for cervical cancer every 5 years, with individuals positive for HPV 16 and/or 18 or other high‐risk HPV types with abnormal cytology referred for colposcopy. Both HPV test and cytology are obtained at the same visit. If HPV is negative, cytology will not be assessed. However, if HPV is positive, both cytology and HPV genotyping will be performed. Colposcopy‐require was defined as HPV 16/18 positivity or abnormal smear results with any hrHPV positivity, and the remaining patients (normal smear with hrHPV positivity other than HPV 16/18) were grouped as colposcopy non‐required. National data on colposcopy outcomes and unnecessary performance rates in February 2018–2019 were evaluated via a questionnaire.ResultsA total of 9808 patients were included, divided based on colposcopy requirement: 5751 (58.6%) patients required colposcopy and 4057 (41.4%) did not. Unnecessary colposcopy was performed on 90.1% of the non‐required group (3657 of 4057 patients). In the colposcopy‐required group, 4455 patients (79.9%) underwent punch biopsy; 3194 (57.1%), endocervical curettage (ECC); and 421 (7.5%), “see and treat” in the non‐required group, the results were 2790 (76.3%), 1957 (53.2%), and 211 (5.7%), respectively. A total of 746 cervical intraepithelial neoplasia (CIN)‐3 isolates were detected, including 702 using existing screening and triage with 94.1% sensitivity (702/746). Multiple biopsies were taken in 69.8% (n = 3110) of patients from the colposcopy‐required group and 63.7% (n = 1777) from the non‐required group. The ECC samples included 19 cervical cancers and 212 ≥CIN‐3 lesions in the colposcopy‐required group, and four cancers and 41 ≥CIN‐3 lesions in the non‐required group. The proportion of ≥CIN‐3 lesions detected by ECC only was 4.7% (35 of 746 ≥CIN‐3 lesions).ConclusionOur results showed high rates of unnecessary colposcopies, and a high percentage of multiple and random punch biopsies and ECC.

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference31 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing

3. Dairesi TCSBK.Serviks Kanseri Tarama Programı Ulusal Standartları 2014.https://hsgm.saglik.gov.tr/depo/Mevzuat/Genel_Nitelikli_Yazi_ve_Gorusler/Serviks_Kanseri_Tarama_Programi_Ulusal_Standartlari.pdf. Accessed November 26 2012.

4. Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3